Radiolabeled nanoparticles for multimodality tumor imaging

Theranostics

Volumn 4, Issue 3, 2014, Pages 290-306

  Xing, Yan ^a,b   Zhao, Jinhua ^b   Conti, Peter S ^a   Chen, Kai ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cancer; Molecular imaging; Multimodality imaging; Radiolabeled nanoparticles; Theranostics; Tumor diagnosis

Indexed keywords

CANCER; MOLECULAR IMAGING; MULTIMODALITY IMAGING; RADIOLABELED NANOPARTICLES; THERANOSTICS; TUMOR DIAGNOSIS;

HUMANS; MAGNETIC RESONANCE IMAGING; MULTIMODAL IMAGING; NANOPARTICLES; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84893523047     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.7341     Document Type: Review

References (97)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. Weissleder R, Mahmood U. Molecular imaging. Radiology. 2001; 219: 316-33.
3. Chen K, Chen X. Design and development of molecular imaging probes. Curr Top Med Chem. 2010; 10: 1227-36.
4. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008; 49 Suppl 2: 113S-28S.
5. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003; 17: 545-80.
6. Cherry SR. Multimodality imaging: beyond PET/CT and SPECT/CT. Semin Nucl Med. 2009; 39: 348-53.
7. Patel CN, Goldstone AR, Chowdhury FU, Scarsbrook AF. FDG PET/CT in oncology: "raising the bar". Clin Radiol. 2010; 65: 522-35.
8. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000; 41: 1369-79.
9. Even-Sapir E, Lerman H, Lievshitz G, Khafif A, Fliss DM, Schwartz A, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med. 2003; 44: 1413-20.
10. Catana C, Wu Y, Judenhofer MS, Qi J, Pichler BJ, Cherry SR. Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. J Nucl Med. 2006; 47: 1968-76.
11. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5: 161-71.
12. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine. 2007; 3: 20-31.
13. Hong H, Zhang Y, Sun J, Cai W. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today. 2009; 4: 399-413.
14. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 2010; 624: 25-37.
15. Chen K, Conti PS. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev. 2010; 62: 1005-22.
16. Gullberg GT, Reutter BW, Sitek A, Maltz JS, Budinger TF. Dynamic single photon emission computed tomography--basic principles and cardiac applications. Phys Med Biol. 2010; 55: R111-91.
17. Miller PW, Long NJ, Vilar R, Gee AD. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew Chem Int Ed Engl. 2008; 47: 8998-9033.
18. Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res. 2009; 42: 832-41.
19. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010; 110: 2858-902.
20. Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol Imaging. 2010; 9: 1-20.
21. Liu S, Edwards DS. 99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. Chem Rev. 1999; 99: 2235-68.
22. Wang Y, Xu C, Ow H. Commercial nanoparticles for stem cell labeling and tracking. Theranostics. 2013; 3: 544-60.
23. Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev. 2012; 41: 2656-72.
24. El-Sayed MA. Some interesting properties of metals confined in time and nanometer space of different shapes. Acc Chem Res. 2001; 34: 257-64.
25. Dykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem Soc Rev. 2012; 41: 2256-82.
26. Khlebtsov N, Bogatyrev V, Dykman L, Khlebtsov B, Staroverov S, Shirokov A, et al. Analytical and theranostic applications of gold nanoparticles and multifunctional nanocomposites. Theranostics. 2013; 3: 167-80.
27. Khlebtsov N, Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev. 2011; 40: 1647-71.
28. Cheki M, Moslehi M, Assadi M. Marvelous applications of quantum dots. Eur Rev Med Pharmaco. 2013; 17: 1141-8.
29. Bruchez M, Jr., Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science. 1998; 281: 2013-6.
30. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007; 25: 1165-70.
31. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect. 2006; 114: 165-72.
32. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science. 1998; 281: 2016-8.
33. Yong KT, Qian J, Roy I, Lee HH, Bergey EJ, Tramposch KM, et al. Quantum rod bioconjugates as targeted probes for confocal and two-photon fluorescence imaging of cancer cells. Nano Lett. 2007; 7: 761-5.
34. Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science. 2002; 298: 1759-62.
35. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004; 22: 969-76.
36. Ling Y, Wei K, Luo Y, Gao X, Zhong S. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials. 2011; 32: 7139-50.
37. Amstad E, Textor M, Reimhult E. Stabilization and functionalization of iron oxide nanoparticles for biomedical applications. Nanoscale. 2011; 3: 2819-43.
38. Louie A. Multimodality imaging probes: design and challenges. Chemical reviews. 2010; 110: 3146-95.
39. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small. 2008; 4: 26-49.
40. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging. 1995; 13: 661-74.
41. Nyk M, Kumar R, Ohulchanskyy TY, Bergey EJ, Prasad PN. High contrast in vitro and in vivo photoluminescence bioimaging using near infrared to near infrared up-conversion in Tm3+ and Yb3+ doped fluoride nanophosphors. Nano Lett. 2008; 8: 3834-8.
42. Zhou J, Sun Y, Du X, Xiong L, Hu H, Li F. Dual-modality in vivo imaging using rare-earth nanocrystals with near-infrared to near-infrared (NIR-to-NIR) upconversion luminescence and magnetic resonance properties. Biomaterials. 2010; 31: 3287-95.
43. Wang F, Banerjee D, Liu Y, Chen X, Liu X. Upconversion nanoparticles in biological labeling, imaging, and therapy. Analyst. 2010; 135: 1839-54.
44. Santra S. Fluorescent silica nanoparticles for cancer imaging. Methods Mol Biol. 2010; 624: 151-62.
45. Yang P, Gai S, Lin J. Functionalized mesoporous silica materials for controlled drug delivery. Chem Soc Rev. 2012; 41: 3679-98.
46. Dai Y, Ma P, Cheng Z, Kang X, Zhang X, Hou Z, et al. Up-conversion cell imaging and pH-induced thermally controlled drug release from NaYF4/Yb3+/Er3+@hydrogel core-shell hybrid microspheres. ACS Nano. 2012; 6: 3327-38.
47. Gai S, Yang PY, Li CX, Wang WX, Dai YL, Niu N, et al. Synthesis of Magnetic, Up-Conversion Luminescent, and Mesoporous Core-Shell-Structured Nanocomposites as Drug Carriers. Adv Funct Mater. 2010; 20: 1166-72.
48. Longmire M, Choyke PL, Kobayashi H. Dendrimer-based contrast agents for molecular imaging. Curr Top Med Chem. 2008; 8: 1180-6.
49. Xu H, Regino CA, Koyama Y, Hama Y, Gunn AJ, Bernardo M, et al. Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fluorescence imaging. Bioconjug Chem. 2007; 18: 1474-82.
50. Koyama Y, Talanov VS, Bernardo M, Hama Y, Regino CA, Brechbiel MW, et al. A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging. 2007; 25: 866-71.
51. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007; 24: 1-16.
52. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001; 73: 137-72.
53. Elbayoumi TA, Torchilin VP. Current trends in liposome research. Methods Mol Biol. 2010; 605: 1-27.
54. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009; 26: 523-80.
55. Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst. 1987; 3: 123-93.
56. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther. 2001; 298: 607-12.
57. Litzinger DC, Buiting AM, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta. 1994; 1190: 99-107.
58. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991; 1068: 133-41.
59. Maham A, Tang Z, Wu H, Wang J, Lin Y. Protein-based nanomedicine platforms for drug delivery. Small. 2009; 5: 1706-21.
60. Uchida M, Flenniken ML, Allen M, Willits DA, Crowley BE, Brumfield S, et al. Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J Am Chem Soc. 2006; 128: 16626-33.
61. Zhang L, Laug L, Munchgesang W, Pippel E, Gosele U, Brandsch M, et al. Reducing stress on cells with apoferritin-encapsulated platinum nanoparticles. Nano Lett. 2010; 10: 219-23.
62. Hosein HA, Strongin DR, Allen M, Douglas T. Iron and cobalt oxide and metallic nanoparticles prepared from ferritin. Langmuir. 2004; 20: 10283-7.
63. Ueno T, Abe M, Hirata K, Abe S, Suzuki M, Shimizu N, et al. Process of accumulation of metal ions on the interior surface of apo-ferritin: crystal structures of a series of apo-ferritins containing variable quantities of Pd(II) ions. J Am Chem Soc. 2009; 131: 5094-100.
64. Geninatti Crich S, Bussolati B, Tei L, Grange C, Esposito G, Lanzardo S, et al. Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res. 2006; 66: 9196-201.
65. Santambrogio P, Levi S, Arosio P, Palagi L, Vecchio G, Lawson DM, et al. Evidence that a salt bridge in the light chain contributes to the physical stability difference between heavy and light human ferritins. J Biol Chem. 1992; 267: 14077-83.
66. Cai W, Chen K, Li ZB, Gambhir SS, Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med. 2007; 48: 1862-70.
67. Chen K, Li ZB, Wang H, Cai W, Chen X. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging. 2008; 35: 2235-44.
68. Nahrendorf M, Keliher E, Marinelli B, Waterman P, Feruglio PF, Fexon L, et al. Hybrid PET-optical imaging using targeted probes. Proc Natl Acad Sci USA. 2010; 107: 7910-5.
69. Nahrendorf M, Waterman P, Thurber G, Groves K, Rajopadhye M, Panizzi P, et al. Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol. 2009; 29: 1444-51.
70. Lin X, Xie J, Niu G, Zhang F, Gao H, Yang M, et al. Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett. 2011; 11: 814-9.
71. Zhang R, Lu W, Wen X, Huang M, Zhou M, Liang D, et al. Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis. J Nucl Med. 2011; 52: 958-64.
72. Liang M, Liu X, Cheng D, Liu G, Dou S, Wang Y, et al. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Bioconjug Chem. 2010; 21: 1385-8.
73. Lee HY, Li Z, Chen K, Hsu AR, Xu C, Xie J, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med. 2008; 49: 1371-9.
74. Choi JS, Park JC, Nah H, Woo S, Oh J, Kim KM, et al. A hybrid nanoparticle probe for dual-modality positron emission tomography and magnetic resonance imaging. Angew Chem Int Ed Engl. 2008; 47: 6259-62.
75. Misri R, Meier D, Yung AC, Kozlowski P, Hafeli UO. Development and evaluation of a dual-modality (MRI/SPECT) molecular imaging bioprobe. Nanomedicine. 2012; 8: 1007-16.
76. Misri R, Saatchi K, Ng SS, Kumar U, Hafeli UO. Evaluation of 111In labeled antibodies for SPECT imaging of mesothelin expressing tumors. Nucl Med Biol. 2011; 38: 885-96.
77. Park JC, Yu MK, An GI, Park SI, Oh J, Kim HJ, et al. Facile preparation of a hybrid nanoprobe for triple-modality optical/PET/MR imaging. Small. 2010; 6: 2863-8.
78. Joshi BP, Wang TD. Exogenous Molecular Probes for Targeted Imaging in Cancer: Focus on Multi-modal Imaging. Cancers. 2010; 2: 1251-87.
79. Xie J, Chen K, Huang J, Lee S, Wang J, Gao J, et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials. 2010; 31: 3016-22.
80. Robertson R, Germanos MS, Li C, Mitchell GS, Cherry SR, Silva MD. Optical imaging of Cerenkov light generation from positron-emitting radiotracers. Phys Medicine Biol. 2009; 54: N355-65.
81. Lee J, Lee TS, Ryu J, Hong S, Kang M, Im K, et al. RGD peptide-conjugated multimodal NaGdF4:Yb3+/Er3+ nanophosphors for upconversion luminescence, MR, and PET imaging of tumor angiogenesis. J Nucl Med. 2013; 54: 96-103.
82. Hwang do W, Ko HY, Lee JH, Kang H, Ryu SH, Song IC, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med. 2010; 51: 98-105.
83. Cherry SR. Multimodality in vivo imaging systems: twice the power or double the trouble? Annu Rev Biomed Eng. 2006; 8: 35-62.
84. Delbeke D, Schoder H, Martin WH, Wahl RL. Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Semin Nucl Med. 2009; 39: 308-40.
85. Jennings LE, Long NJ. 'Two is better than one'--probes for dual-modality molecular imaging. Chem Commun (Camb). 2009;: 3511-24.
86. Lee S, Chen X. Dual-modality probes for in vivo molecular imaging. Mol Imaging. 2009; 8: 87-100.
87. Majumdar D, Peng XH, Shin DM. The medicinal chemistry of theragnostics, multimodality imaging and applications of nanotechnology in cancer. Curr Top Med Chem. 2010; 10: 1211-26.
88. Shin SJ, Beech JR, Kelly KA. Targeted nanoparticles in imaging: paving the way for personalized medicine in the battle against cancer. Integr Biol-UK. 2013; 5: 29-42.
89. Cai H, Li Z, Huang CW, Shahinian AH, Wang H, Park R, et al. Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression. Bioconjug Chem. 2010; 21: 1417-24.
90. Cai H, Li Z, Huang CW, Park R, Shahinian AH, Conti PS. An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)be nzoic acid, for 64Cu radiopharmaceuticals. Nucl Med Biol. 2010; 37: 57-65.
91. Choi HS, Frangioni JV. Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol Imaging. 2010; 9: 291-310.
92. Kolosnjaj J, Szwarc H, Moussa F. Toxicity studies of carbon nanotubes. Adv Exp Med Biol. 2007; 620: 181-204.
93. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. Drug Discov Today. 2003; 8: 1128-37.
94. Kolb HC, Finn MG, Sharpless KB. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl. 2001; 40: 2004-21.
95. Zeng D, Lee NS, Liu Y, Zhou D, Dence CS, Wooley KL, et al. 64Cu Core-labeled nanoparticles with high specific activity via metal-free click chemistry. ACS Nano. 2012; 6: 5209-19.
96. Chen K, Wang X, Lin W, Shen C, Yap L, Hughes LD, et al. Strain-Promoted Catalyst-Free Click Chemistry for Rapid Construction of 64Cu-Labeled PET Imaging Probes. ACS Med Chem Lett. 2012; 3: 1019-23.
97. Ahmed N, Fessi H, Elaissari A. Theranostic applications of nanoparticles in cancer. Drug Discov Today. 2012; 17: 928-34.